|
|
|
|
|
|
|
|
|
|
abstract
Conclusion The advantage of IP over intravenous chemotherapy extends beyond 10 years. IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number of IP cycles.
Wednesday, April 29, 2015
Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: GOG
abstract
Conclusion The advantage of IP over intravenous chemotherapy extends beyond 10 years. IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number of IP cycles.
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.